[Prognosis for therapeutic effectiveness of radiotherapy in the combined treatment of cancer].
The efficacy of radiotherapy and chemoradiotherapy for patients with breast cancer and combined treatment for bladder cancer was evaluated by means of as-blood test (Sbl). It points to magnitude of radiation-induced decay of peripheral blood DNA in vitro prior to therapy. Level of DNA decay was evaluated after exposure to 2Gy and 3-hr incubation. The index in excess of 1.0 (in radiation-sensitive patients) was followed by a relapse-free survival 1.5-2 times longer (5-32 months depending on pathology) than in radiation-resistant patients. Also, a relationship was established between Sbl index and leukopenia level, as an indicator of hematoxic effect of radio- and chemotherapy on patients with bladder cancer and Hodgkin's disease. Hence, Sbl may be used to individualize a therapeutic modality including radiotherapy and, if necessary, to provide for use of hemostimulators.
Ivanov
S D
SD
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D001943:Breast Neoplasms / Q000097:blood / Q000532:radiotherapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D015653:Cystectomy / Q000379:methods; D004273:DNA, Neoplasm / Q000187:drug effects / Q000528:radiation effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008408:Mastectomy / Q000379:methods; D008875:Middle Aged; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000097:blood / Q000532:radiotherapy* / Q000601:surgery
D004273:DNA, Neoplasm